Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications. Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, ...
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical ...
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results